Economic Evaluation of a Neural Tube Defect Recurrence-Prevention Program

American Journal of Preventive Medicine

Volumn 35, Issue 6, 2008, Pages 572-577

  Grosse, Scott D ^a   Ouyang, Lijing ^a   Collins, Julianne S ^b   Green, Denise ^a   Dean, Jane H ^b   Stevenson, Roger E ^b  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b GREENWOOD GENETIC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; MULTIVITAMIN;

ARTICLE; BIRTH DEFECT; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; HEALTH CARE COST; HEALTH PROGRAM; NEURAL TUBE DEFECT; PREGNANCY; PRENATAL CARE; RECURRENT DISEASE; UNITED STATES;

COST-BENEFIT ANALYSIS; COUNSELING; FEMALE; FOLIC ACID; FOOD, FORTIFIED; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NEURAL TUBE DEFECTS; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY OUTCOME; PRENATAL CARE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISK FACTORS; SOUTH CAROLINA; VITAMIN B COMPLEX;

EID: 55349097084     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2008.07.008     Document Type: Article

References (40)

1. Medical Research Council Vitamin Study Research Group. Prevention of neural tube defects: results of the medical research council vitamin study. Lancet 338 (1991) 131-137
2. Rowland C.A., Correa A., Cragan J.D., and Alverson C.J. Are encephaloceles neural tube defects?. Pediatrics 118 (2006) 916-923
3. Little J. Risks in siblings and other relatives. In: Elwood J.M., Little J., and Elwood J.H. (Eds). Epidemiology and control of neural tube defects (1992), Oxford University Press, Oxford 604-676
4. Grosse S.D., and Collins J.S. Folic acid supplementation and neural tube defect recurrence prevention. Birth Def Res Part A 79 (2007) 737-742
5. Dean J.H., Collins J.S., Clary N.J., and Stevenson R.E. Preventing the recurrence of neural tube defects in South Carolina. Proc Greenwood Genet Center 26 (2007) 40-44
6. Felkner M., Suarez L., Hendricks K., and Larsen R. Implementation and outcomes of recommended folic acid supplementation in Mexican-American women with prior neural tube defect-affected pregnancies. Prev Med 40 (2005) 867-871
7. Vergel R.G., Sanchez L.R., Heredero B.L., et al. Primary prevention of neural tube defects with FA supplementation: Cuban experience. Prenat Diagn 10 (1990) 149-152
8. CDC. Use of folic acid for prevention of spina bifida and other neural tube defects-1983-1991. MMWR Morb Mortal Wkly Rep 40 (1991) 513-516
9. CDC. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 41 (1992) 1-7
10. CDC. Use of vitamins containing folic acid among women of childbearing age-U.S., 2007. MMWR Morb Mortal Wkly Rep 57 (2008) 5-8
11. Canfield M.A., Anderson J.L., Waller D.K., et al. Folic acid awareness and use among women with a history of a neural tube defect pregnancy-Texas, 2000-2001. MMWR Recomm Rep 51 (2002) 16-19
12. Callender E.S., Rickard R., Miller L., and Rinsky-Eng J. Knowledge and use of folic acid supplementation: a study of Colorado women whose pregnancies were affected by a fetal neural tube defect. Clin Invest Med 24 (2001) 124-128
13. Stevenson R.E., Allen W.P., Pai G.S., et al. Decline in prevalence of neural tube defects in a high-risk region of the U.S. Pediatrics 106 (2000) 677-683
14. U.S. Bureau of Labor Statistics. Employment cost trends. www.bls.gov/ncs/ect/#tables
15. Bol K.A., Collins J.S., Kirby R.S., and National Birth Defects Prevention Network. Survival of infants with neural tube defects in the presence of folic acid fortification. Pediatrics 117 (2006) 803-813
16. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
17. Luce B.R., Manning W.G., Siegel J.E., and Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
18. Harris R.A., Washington A.E., Nease Jr. R.F., and Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 363 (2004) 276-282
19. CDC. Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects-U.S., 2003. MMWR Morb Mortal Wkly Rep 56 (2007) 25-29
20. Russo C.A., and Elixhauser A. Hospitalizations for birth defects, 2004. HCUP Statistical Brief #24 (2007), U.S. Agency for Healthcare Research and Quality, Rockville MD. www.hcup-us.ahrq.gov
21. Waitzman N.J., Scheffler R.M., and Romano P.S. The costs of birth defects: estimates of the value of prevention (1996), University Press of America, Inc, Lanham MD
22. Waitzman N.J., Romano P.S., and Grosse S.D. Half-life of cost of illness estimates: the case of spina bifida. In: Wyszynski D.F. (Ed). Neural tube defects: from origin to treatment (2005), Oxford University Press, New York
23. Grosse S.D., Waitzman N.J., Romano P.S., and Mulinare J. Reevaluating the benefits of folic acid fortification in the U.S.: economic analysis, regulation, and public health. Am J Public Health 95 (2005) 1917-1922
24. Ouyang L., Grosse S.D., Armour B.S., and Waitzman N.J. Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. Birth Def Res Part A 79 (2007) 552-558
25. Tilford J.M., Grosse S.D., Goodman A.C., and Li K. Labor market productivity costs for caregivers of children with spina bifida: a population-based analysis. Med Decis Making (2008) Aug 25. [Epub ahead of print]
26. Shepard C.W., Ortega-Sanchez I.R., Scott II R.D., et al. Cost-effectiveness of conjugate meningococcal vaccination strategies in the U.S. Pediatrics 115 (2005) 1220-1232
27. Tilford J.M., Grosse S.D., Robbins J.M., et al. Health state preference scores of children with spina bifida and their caregivers. Qual Life Res 14 (2005) 1087-1098
28. Kelly A.E., Haddix A.C., Scanlon K.S., Helmick C.G., and Mulinare J. Cost-effectiveness of strategies to prevent neural tube defects. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
29. Forrester M.B., and Merz R.D. Precurrence risk of neural tube defects in siblings of infants with lipomyelomeningocele. Genet Med 7 (2005) 457
30. Rinsky-Eng J., and Miller L. Knowledge, use, and education regarding folic acid supplementation: continuation study of women in Colorado who had a pregnancy affected by a neural tube defect. Teratology 66 1S (2002) S29-S31
31. Grosse S.D., Teutsch S.M., and Haddix A.C. Lessons from cost-effectiveness research for U.S. public health policy. Annu Rev Public Health 28 (2007) 365-391
32. Grosse S.D. Assessing cost effectiveness in health care: the history of the $50,000 per QALY threshold. Exp Rev Pharmacoeconomics Outcome Res 8 (2008) 165-178
33. Braithwaite R.S., Meltzer D., King Jr. J.T., Leslie D., and Roberts M.S. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care 46 (2008) 349-356
34. Weinstein M.C. How much are Americans willing to pay for a quality-adjusted life year?. Med Care 46 (2008) 343-345
35. Maciosek M.V., Coffield A.B., Edwards N.M., Flottemesch T.J., Goodman M.J., and Solberg L.I. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 31 (2006) 52-61
36. Romano P.S., Waitzman N.J., Scheffler R.M., and Pi R.D. Folic acid fortification of grain: an economic analysis. Am J Public Health 85 (1995) 667-676
37. Postma M.J., Londeman J., Veenstra M., and de Jong L.T. Cost-effectiveness of periconceptual supplementation of folic acid. Pharm World Sci 24 (2002) 8-11
38. Llanos A., Hertrampf E., Cortes F., Pardo A., Grosse S.D., and Uauy R. Cost-effectiveness of a folic acid fortification program in Chile. Health Policy 83 (2007) 295-303
39. Committee on Medical Aspects of Food and Nutrition Policy (COMA). Folic acid and the prevention of disease (2000), The Stationery Office, London
40. Istituto Superiore di Sanità. Folic acid: from research to public health practice. Edited by Domenica Taruscio. Rome. Rapporti ISTISAN 04/26, 2004. Istituto Superiore della Sanita, Rome. ISSN 1123-31127. www.iss.it/binary/acid/cont/ISTISAN%2004-26.1151073536.pdf